Home
Genrix Bio

Genrix Bio Market Share Analysis for May 2026

Industry: N/A

Domaingenrixbio.com

Year Founded--

Employees51 - 200

Annual Revenue--

Genrix Bio

Genrix Bio (including company regionals)

genrixbio.com

See more website traffic and engagement information

Total visits to Genrix Bio's top domains

Understand Genrix Bio market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Genrix Bio's top domains

Analyze Genrix Bio engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Genrix Bio's top domains

See how Genrix Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Genrix Bio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Genrix Bio

These are the website technologies, by industry, used by Genrix Bio top domains

Content Management System (2)

WordPress

Advertising (1)

Baidu Ads

Conversion & Analytics (1)

Baidu Analytics

Email Services (1)

QQ Mail

More Technologies

2

See all

News & Signals from Genrix Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsGenrixbio partnered with Zikooint on Sep 7th '25.Recently, Genrix Bio partnered with Zikoo Robotics to build a GMP/GSP-compliant smart warehouse, setting a new benchmark for digital transformation in the pharmaceutical industry.

NewsCullinan Therapeutics, Inc partnered with Genrixbio on Jun 5th '25.CAMBRIDGE, MA, USA I June 04, 2025 I Cullinan Therapeutics, Inc. (Nasdaq: CGEM; "Cullinan"), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T cell engager.